human glucagon-like peptide-1 + fibroblast growth factor 21 adipose-derived stem cell injection

human glucagon-like peptide-1 + fibroblast growth factor 21 adipose-derived stem cell injection is an innovative gene-modified cell therapy developed by Beijing Jiyuan Biotechnology for the treatment of type 2 diabetes mellitus. The therapy utilizes human adipose-derived stem cells (ADSCs) that have been genetically engineered to overexpress two key metabolic regulators: human glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21). GLP-1 acts as an incretin mimetic, enhancing glucose-dependent insulin secretion and promoting pancreatic beta-cell survival, while FGF21 improves insulin sensitivity, regulates lipid metabolism, and reduces hepatic glucose production. By using ADSCs as a delivery vehicle, the therapy aims to provide a sustained release of these therapeutic proteins (a "biopump" effect) while also leveraging the inherent immunomodulatory and regenerative properties of mesenchymal stem cells to address the underlying pathophysiology of diabetes.

Other names

GLP-1 and FGF21 dual-gene modified adipose-derived mesenchymal stem cellsGLP1 and FGF21 dual-gene modified adipose-derived mesenchymal stem cellsGLP 1 and FGF21 dual-gene modified adipose-derived mesenchymal stem cellshGLP-1-FGF21-modified ADSCshGLP1-FGF21-modified ADSCshGLP 1-FGF21-modified ADSCshGLP-1-FGF21-modified adipose-derived stem cellshGLP1-FGF21-modified adipose-derived stem cellshGLP 1-FGF21-modified adipose-derived stem cells